Give every patient access to the most advanced cancer care

You’re committed to delivering the best patient care today, and tomorrow. Partnering with Personalis provides comprehensive genomic testing today, and ensures your testing capabilities will grow as the field of oncology evolves. We’re committed to empowering your treatment decisions through highly sensitive and ultra-comprehensive genomic profiling.

Access Portal

Test Background

Suitable for any patient with a solid tumor, the NeXT Dx test is a comprehensive genomics tumor profiling test based on augmented whole exome and transcriptome sequencing.

It works by analyzing the tumor’s genomic and molecular characteristics using clinical-grade, next-generation sequencing (NGS) technology to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), fusions, MSI and exome-wide “true” TMB. Mutations in certain genes that may be germline in origin are reported as incidental findings. In addition, mutations in genes involved in homologous recombination repair (HRR) are highlighted when identified. A list of genes covered by the NeXT Dx test may be found here.

Industry Challenges

Many false positive variants
due to tumor-only approach

No germline variants
reported from tumor-only tests

Misses actionable mutations

Looks at DNA only

Difficult to add new biomarkers

TMB requires extrapolation
from panels

NeXT Dx™ Test Solution

Matched tumor-normal approach accurately identifies somatic variants

Germline variants are reported
as incidental findings

Fills in sequencing gaps left
by other testing solutions

Analyzes both DNA and RNA

Faster integration of new biomarkers

Gold-standard exome wide
TMB assessment

1. Solomon et al., Modern Pathology, 2020


What it Looks Like

Our easy-to-interpret report puts all clinically relevant alterations on the first page.
Click the callouts below to see more in detail.

    Easily scannable.

    All clinically relevant variants available at-a-glance on the first page. Drug indications, potential clinical trials and variant allele fractions are in one table.

    Germline Reporting

    Pathogenic and likely pathogenic germline variants in certain genes are reported as incidental findings

    Microsatellite Instability (MSI) Reported

    MSI results are reported as High or Stable based on 117 loci.

    Gold Standard TMB

    True exome-wide TMB results are reported based on tumor-normal analysis.

    Confidence in Results

    Clinically relevant negatives are reported according to the patient’s tumor type.

    Drug Response

    Up-to-date drug sensitivity and resistance recommendations are summarized. Sources include FDA, NCCN, and ASCO.

    Clinical Trials

    A custom-generated list of clinical trial matches is provided.

    Additional information, at your fingertips.

    Clickable hyperlinks direct to entries on and contact details for trial sponsor.

Download Sample Report


For all other questions, please visit our Clinician FAQs

Clinician FAQ

Additional Resources

Contact Information

Client Services

+1 (855) 373-7978 or [email protected]
6:00 a.m. – 5:00 p.m. PST, weekdays.

Patient Billing Services

+1 (855) 373-7974 or [email protected]
6:30 a.m. – 4:00 p.m. PST, weekdays.